Emergent BioSolutions Inc. - Common Stock (EBS) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
EBS on NYSE
Shares outstanding
54,486,781
Price per share
$12.36
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
41,696,731
Total reported value
$352,475,779
% of total 13F portfolios
0%
Share change
+2,028,888
Value change
+$19,667,118
Number of holders
167
Price from insider filings
$12.36
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Emergent BioSolutions Inc. - Common Stock (EBS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.3% $25,376,673 3,977,535 BlackRock, Inc. 30 Jun 2025

As of 30 Sep 2025, 167 institutional investors reported holding 41,696,731 shares of Emergent BioSolutions Inc. - Common Stock (EBS). This represents 77% of the company’s total 54,486,781 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Emergent BioSolutions Inc. - Common Stock (EBS) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 7.8% 4,263,123 -2.2% 0% $37,600,745
OAK HILL ADVISORS LP 6.6% 3,613,338 0% 3.5% $16,566,289
VANGUARD GROUP INC 6.5% 3,540,670 -1.2% 0% $31,228,709
STATE STREET CORP 4.5% 2,445,759 +40% 0% $21,571,594
AMERICAN CENTURY COMPANIES INC 4.4% 2,382,378 +3.9% 0.01% $21,012,574
DIMENSIONAL FUND ADVISORS LP 3.9% 2,140,340 +16% 0% $18,878,293
PALISADE CAPITAL MANAGEMENT, LP 2.6% 1,426,019 +30% 0.34% $12,577,488
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 2.5% 1,381,750 +25% 0% $12,187,035
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,278,693 -0.02% 0% $11,280,337
ACADIAN ASSET MANAGEMENT LLC 2.2% 1,177,661 +21% 0.02% $10,383,000
Connor, Clark & Lunn Investment Management Ltd. 2.1% 1,132,305 +15% 0.03% $9,986,930
MARSHALL WACE, LLP 1.7% 912,388 -10% 0.01% $8,047,261
LSV ASSET MANAGEMENT 1.6% 864,500 +6% 0.02% $7,625,000
Prescott Group Capital Management, L.L.C. 1.4% 772,771 0% 0.72% $6,815,840
NORTHERN TRUST CORP 1.2% 637,832 +43% 0% $5,625,679
GOLDMAN SACHS GROUP INC 1.1% 620,977 +7.2% 0% $5,477,017
AQR CAPITAL MANAGEMENT LLC 1.1% 586,246 0% $5,170,690
Pacer Advisors, Inc. 0.98% 536,655 -3.6% 0.01% $4,733,297
MORGAN STANLEY 0.97% 528,875 -28% 0% $4,664,686
Trexquant Investment LP 0.97% 526,288 -4.6% 0.05% $4,641,860
NEW YORK STATE COMMON RETIREMENT FUND 0.96% 522,004 +33% 0.01% $4,604,075
RENAISSANCE TECHNOLOGIES LLC 0.95% 518,247 -25% 0.01% $4,570,939
Jain Global LLC 0.93% 508,707 0.06% $4,486,796
UBS Group AG 0.81% 439,375 -9.2% 0% $3,875,288
FEDERATED HERMES, INC. 0.74% 401,258 +44% 0.01% $3,539,096

Institutional Holders of Emergent BioSolutions Inc. - Common Stock (EBS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 389,792 $4,806,818 +$1,452,009 $12.36 16
2025 Q3 41,696,731 $352,475,779 +$19,667,118 $8.82 167
2025 Q2 36,048,259 $229,963,501 +$8,627,423 $6.38 159
2025 Q1 36,190,861 $175,869,555 +$2,175,881 $4.86 158
2024 Q4 34,731,466 $332,026,231 +$28,116,282 $9.56 155
2024 Q3 31,685,912 $264,526,545 +$30,958,222 $8.35 137
2024 Q2 30,424,097 $207,508,937 -$26,587,800 $6.82 137
2024 Q1 35,915,952 $90,810,710 -$12,044,764 $2.53 115
2023 Q4 40,884,124 $98,125,874 -$3,033,553 $2.40 129
2023 Q3 41,326,491 $140,783,681 -$26,266,322 $3.40 159
2023 Q2 45,670,504 $335,708,725 +$1,389,547 $7.35 177
2023 Q1 44,931,082 $465,319,997 -$16,940,760 $10.36 187
2022 Q4 46,237,482 $546,050,427 +$42,157,405 $11.81 193
2022 Q3 40,630,823 $852,783,613 -$48,608,549 $20.99 192
2022 Q2 41,191,389 $1,278,322,431 -$19,204,360 $31.04 217
2022 Q1 41,761,849 $1,714,987,525 -$22,633,768 $41.06 234
2021 Q4 42,514,559 $1,849,372,320 -$107,864,716 $43.47 243
2021 Q3 44,511,870 $2,228,860,734 -$18,391,350 $50.07 270
2021 Q2 44,739,294 $2,817,444,749 -$43,662,628 $62.99 286
2021 Q1 44,459,246 $4,122,801,151 +$64,719,540 $92.91 334
2020 Q4 44,267,661 $3,967,537,088 +$93,758,805 $89.60 350
2020 Q3 42,899,052 $4,434,039,819 -$189,544,769 $103.33 355
2020 Q2 53,497,347 $4,185,752,138 +$625,343,109 $79.08 295
2020 Q1 44,884,797 $2,596,632,152 +$7,885,727 $57.86 257
2019 Q4 44,601,650 $2,406,425,656 -$6,082,616 $53.95 232
2019 Q3 44,748,551 $2,338,743,757 -$21,935,074 $52.28 241
2019 Q2 45,520,096 $2,198,644,219 +$64,447,863 $48.31 229
2019 Q1 44,845,040 $2,265,671,390 +$80,862,293 $50.52 265
2018 Q4 43,083,866 $2,553,149,934 +$34,101,099 $59.28 293
2018 Q3 42,429,433 $2,792,382,193 +$14,853,355 $65.83 269
2018 Q2 42,572,970 $2,149,894,709 +$23,723,394 $50.49 257
2018 Q1 42,080,510 $2,209,520,816 +$57,029,193 $52.65 270
2017 Q4 40,397,491 $1,878,364,516 +$151,859,986 $46.47 234
2017 Q3 37,088,695 $1,500,432,961 +$64,446,291 $40.45 193
2017 Q2 35,621,344 $1,199,488,524 +$6,414,221 $33.91 179
2017 Q1 35,579,837 $1,033,330,673 +$100,066,486 $29.04 173
2016 Q4 35,742,013 $1,173,028,889 -$3,279,137 $32.84 204
2016 Q3 35,869,477 $1,129,692,915 -$1,485,647 $31.53 197
2016 Q2 36,161,934 $1,016,934,072 +$82,512,424 $28.12 215
2016 Q1 33,583,921 $1,221,359,935 +$19,065,121 $36.35 211
2015 Q4 32,446,135 $1,298,005,471 +$24,674,059 $40.01 202
2015 Q3 32,168,577 $916,516,058 +$35,690,135 $28.49 191
2015 Q2 31,043,093 $1,022,845,909 +$25,560,178 $32.95 181
2015 Q1 30,395,864 $874,182,011 +$38,137,574 $28.76 169
2014 Q4 29,096,913 $792,405,069 -$719,286 $27.23 163
2014 Q3 28,825,281 $614,994,160 -$30,742 $21.31 158
2014 Q2 28,744,311 $645,587,994 -$436,657 $22.46 157
2014 Q1 28,580,751 $722,288,209 +$89,513,027 $25.27 163